In what subtypes of cancer have we validated the efficacy of comprehensive NGS screening for improving outcomes by aligning molecular targets with appropriate therapies and predictive biomarkers of efficacy? (Korean)

In what subtypes of cancer have we validated the efficacy of comprehensive NGS screening for improving outcomes by aligning molecular targets with appropriate therapies and predictive biomarkers of efficacy? (Korean)

In what subtypes of cancer have we validated the efficacy of comprehensive NGS screening for improving outcomes by aligning molecular targets with appropriate therapies and predictive biomarkers of efficacy?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Seung Tae Kim, MD

Seung Tae Kim, MD

Division of Hematology Oncology
Department of Medicine
Samsung Medical Center
Sungkyunkwan University School of Medicine
Seoul, Korea